Preclinical Biotechs Face a Funding Market that Rewards Stronger Proof

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more

Cell therapy product development is entering a more nuanced regulatory phase as agencies acknowledge the difficulty of applying conventional development expectations to living products. For sponsors, the message is not that standards are lower. Evidence must be planned carefully enough to support flexibility where scientific and manufacturing realities justify it. FDA’s 2026 guidance activity reflects this direction. The agency’s cellular and gene therapy guidance page lists several recent documents, including final guidance on CMC flexibilities for BLA development and draft guidance on leveraging prior knowledge in human gene therapy products incorporating genome editing. The CMC guidance is especially important for cell therapy developers because these products can be difficult to characterize in the same way as traditional biologics. Living cells may vary by donor, patient condition, manufacturing step and analytical method. Developers must define which variations are acceptable and which could affect safety or efficacy. Regulatory flexibility can help smaller companies and rare disease developers, but it also requires a stronger scientific explanation. Sponsors need to show why a proposed approach is reasonable, how quality will be controlled and what evidence supports product understanding. A flexible pathway without a strong rationale can create risk during review. Recent regulatory reporting has noted that the FDA released a final guidance document with immediate effect, advising sponsors on CMC flexibilities for cell and gene therapy products developed for BLAs. The same coverage described the document as part of a more flexible approach to clinical development, commercial specifications and process validation. This matters because cell therapy programs often evolve through development. A company may improve a process, change an assay or shift manufacturing sites as it moves toward later trials. Each change can trigger questions about comparability. Sponsors that maintain strong development records are better positioned to explain why the product remains sufficiently comparable after change. Potency remains one of the most difficult challenges in cell and gene therapy development. It is not enough to show that a product has certain characteristics. Developers also need tests that demonstrate those characteristics are linked to the intended biological activity. When potency testing is not well established, it can create uncertainty even if early clinical results look encouraging. That is why many developers treat assay development as an ongoing process, refining and strengthening it as the product advances through development. The next stage of cell therapy product development will likely reward sponsors that engage regulators early and document decisions clearly. Flexibility can support innovation, but only when paired with evidence and transparency. For the sector, regulatory flexibility is best viewed as an opportunity to plan more effectively rather than as a shortcut. It gives developers the ability to adapt as products evolve, but that flexibility also makes a well-structured CMC strategy even more important from the earliest stages of development. Starting with a disciplined approach helps teams make changes with confidence while keeping product quality and regulatory expectations firmly in view. ...Read more

Cell therapy product development is becoming more manufacturing-led as companies recognize that clinical promise can weaken if process design is not addressed early. Developers are moving beyond a research-first mindset and placing greater attention on scalability, product consistency, release testing and manufacturing evidence before late-stage trials. The market context supports this shift. The global cell therapy manufacturing market is estimated at USD 6.51 billion in 2026 and is projected to reach USD 17.65 billion by 2033, according to Coherent Market Insights. Growth is being shaped by demand across autologous and allogeneic therapies, along with development activity in oncology, musculoskeletal conditions, cardiovascular disease, neurological conditions and other areas. For developers, the manufacturing process looks very different depending on the type of therapy being produced. Autologous therapies require each patient's cells to be collected, processed and returned through a carefully coordinated, individualized workflow. Allogeneic therapies, by contrast, are designed for larger-scale production but bring their own challenges around batch manufacturing and immune compatibility. In both cases, success depends on building manufacturing processes that are reliable enough to support clinical development while remaining practical to scale as therapies move toward commercialization. The problem often appears when early research methods are carried too far into development. Manual steps may work in a small study, but become difficult to reproduce later. A release assay may be acceptable for early-stage work but insufficient for a broader program. Raw material variation can also affect performance if it is not understood early. Regulators are placing more attention on chemistry, manufacturing and controls. The FDA issued final guidance in May 2026 on CMC flexibilities for human cellular and gene therapy products being developed for biologics license applications. The guidance describes how the agency applies flexibility to CMC requirements under BLA development. Developers still need to show that the product can be made consistently and that critical quality attributes are understood. Process changes during development must be justified and documented. Sponsors that wait too long to define their manufacturing strategy may face comparability questions that slow progress. Technology is also changing the development environment. At BIO 2026, cell and gene therapy companies discussed using AI and data systems to improve manufacturing work, pointing to a sector where digital tools are becoming more relevant to production learning. The business implication is clear. Cell therapy product development is no longer only about biology and clinical response. It is also about whether a company can build a repeatable product pathway. The next phase will favor developers who treat manufacturing as part of product identity from the start. In cell therapy, a strong clinical idea must be supported by a process that can survive scale, scrutiny and real patient delivery. ...Read more

When choosing evidence generation software, there is usually a focus on finding the right technology. However, once the contract is signed, a number of challenges arise. It seems that, in recent years, many biopharma companies start paying more attention to the implementation burden related to evidence programs. There are a number of issues that need to be considered at the beginning of implementation. First of all, biopharma organizations tend to have different ways of managing research programs. There can be different workflows in place for R&D functions. Medical affairs may have their own documentation rules. Systems that are used in other areas of operations can also impact implementation. In such conditions, introducing new software involves not only deploying the program. Sometimes, biopharma companies need to adjust processes, redefine the roles, define how information flows within the organization and so on. This step tends to require more time than expected initially. In case of evidence generation programs, the problem may be even more complicated. Research activities that need to be managed can sometimes last for years. Thus, any changes implemented during the transition process can potentially impact ongoing projects, upcoming research initiatives and internal reporting procedures. Another issue that should be discussed is training. Even when the software is designed well, the adoption success largely depends on the ability of users to implement it properly. Otherwise, they can continue relying on spreadsheets or other tools that seem more efficient to them. Increasingly, many biopharma organizations understand that adoption success can depend more on governance factors than product features itself. Ownership, oversight and other process-related questions become very important during adoption, especially if the organization lacks experience in implementing a particular type of software. This aspect is not always considered when buyers evaluate different platforms. All this makes the process of choosing evidence software more complicated than ever. Procurement discussions tend to become focused on implementation considerations. Biopharma organizations pay less attention to product selection and more focus on deployment and adoption challenges. While still being an important component, technological features become less crucial. Providers of such solutions face certain difficulties too. They cannot always predict what customers' expectations will be in terms of configurability, customization and adaptation to organizational needs. However, the implementation burden is here to stay. The growing complexity of evidence programs leads biopharma organizations to explore better software solutions. However, adoption success will largely depend not on features but other aspects mentioned above. Therefore, the implementation strategy plays a key role today. For most biopharma organizations, the main question is not whether the software can help manage research activities. Instead, it is the question about how much efforts will need to be made. ...Read more